HIGHLIGHTS
- who: George Blanck from the University of Houston, United States have published the research: Time to consider sequencing anti-inflammatory treatments with chemotherapy and immuno-stimulation?, in the Journal: (JOURNAL)
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
SUMMARY
Immuno-stimulatory therapies, such as immune checkpoint blockade (ICB), often presuppose the availability of a T-cell receptor (TCR) that can bind a cancer antigen or available antibodies to complete an antibody . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.